One such signaling pathway is that involving the Ca2+/calmodulin (CaM)-dependent protein kinase (CaMKII), which targets and functionally regulates a number of proteins that are central to cardiac excitation-contraction coupling (ECC), and has been identified as a promising new target for antiarrhythmic therapy in patients with heart failure (Rokita and Anderson, 2012). This evidence concerns the gene CAMK2G and heart failure.